D-0315-2021 Class I Terminated

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0315-2021 was initiated by Zydus Pharmaceuticals (USA) Inc on Feb 18, 2021 and is designated Class I. Reason for recall: Crystallization: customer complaints for crystallization in finished product. The recall status is terminated (terminated Nov 23, 2022). Affected quantity: 816 packs.

Recall details

Product Type
Drugs
Report Date
Apr 7, 2021
Initiation Date
Feb 18, 2021
Termination Date
Nov 23, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
816 packs

Product description

Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Reason for recall

Crystallization: customer complaints for crystallization in finished product.

Distribution pattern

USA Nationwide

Code information

Lot#: L000155, Exp 12/2021; L000156, Exp 1/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0315-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0315-2021. Report a data issue: hello@regdatalab.com.